Journal article
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
Abstract
BACKGROUND: Amplification of the human epidermal growth factor receptor type 2 (HER2, also called HER2/neu) gene and overexpression of its product in breast-cancer cells may be associated with responsiveness to anthracycline-containing chemotherapy regimens.
METHODS: In the randomized, controlled Mammary.5 trial, we studied 639 formalin-fixed paraffin-embedded specimens obtained from 710 premenopausal women with node-positive breast cancer who …
Authors
Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN
Journal
The New England Journal of Medicine, Vol. 354, No. 20, pp. 2103–2111
Publisher
Massachusetts Medical Society
Publication Date
May 18, 2006
DOI
10.1056/nejmoa054504
ISSN
0028-4793
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAnthracyclinesAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideEpirubicinFemaleFluorouracilGene AmplificationGene Expression Regulation, NeoplasticGenes, erbB-2HumansMethotrexateMiddle AgedPremenopausePrognosisReceptor, ErbB-2Survival Analysis